Open Access Full Text Article

RETRACTION

IL-6/STAT3 Signaling Contributes to Sorafenib Resistance in Hepatocellular Carcinoma Through Targeting Cancer Stem Cells [Retraction]

Li Y, Chen G, Han Z, Cheng H, Qiao L, Li Y. Onco Targets Ther. 2020;13:9721-9730.

The Editor and Publisher of *OncoTargets and Therapy* wish to retract the published article. Concerns were raised regarding the alleged duplication of western blot images in Figure 4. Specifically,

• Western blot band Figure 4C, IL-6R, Ctrl appears to have been duplicated with western blot band Figure 4E, VEGF, PBS, which has been flipped.

The authors responded to our queries and provided several files. However, the authors were unable to provide a satisfactory explanation for the alleged duplication, nor could they provide satisfactory original western blot data that would support the integrity of their research. The decision was made to retract the article and the authors were notified of this.

Our decision-making was informed by our policy on publishing ethics and integrity and the COPE guidelines on retraction.

The retracted article will remain online to maintain the scholarly record, but it will be digitally watermarked on each page as "Retracted".

OncoTargets and Therapy

Dovepress

871

Publish your work in this journal

OncoTargets and Therapy is an international, peer-reviewed, open access journal focusing on the pathological basis of all cancers, potential targets for therapy and treatment protocols employed to improve the management of cancer patients. The journal also focuses on the impact of management programs and new therapeutic agents and protocols on patient perspectives such as quality of life, adherence and satisfaction. The management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit http://www.dovepress.com/testimonials.php to read real quotes from published authors.

Submit your manuscript here: https://www.dovepress.com/oncotargets-and-therapy-journal

https://doi.org/10.2147/OTT.S386447

Received: 16 August 2022 Accepted: 16 August 2022 Published: 22 August 2022

OncoTargets and Therapy 2022:15 871

© 2022 Dove Medical Press. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/ the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraph 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).